Fried Frank Assists On Catalent's $315M Deal For Masthercell
Drug development and delivery company Catalent, working with Fried Frank, has agreed to pay $315 million to pick up private equity-backed cell and gene therapy developer Masthercell Global, the companies said...To view the full article, register now.
Already a subscriber? Click here to view full article